UNLIMITED TURBO BULL - NOVO-NORDISK B | Market Closed - Euronext Paris 12:30:01 2024-05-17 pm EDT | ||
| 0.78 EUR | -8.77% |
|
| Current month | +4.76% | ||
| 1 month | +36.28% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 0.77 | -9.94% |
| 24-05-16 | 0.855 | -2.84% |
| 24-05-15 | 0.88 | +2.92% |
| 24-05-14 | 0.855 | +1.18% |
| 24-05-13 | 0.845 | +19.01% |
Real-time Euronext Paris
Last update May 17, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| 6B69S | |
| ISIN | DE000SU9LYF0 |
| Date issued | 2024-02-20 |
| Strike | 787.4 kr |
| Maturity | Unlimited |
| Parity | 20 : 1 |
| Emission price | 0.55 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.165 € |
|---|---|
| Lowest since issue | 0.245 € |
| Spread | 0.69 € |
| Spread % | 48.25% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
903.3
DKK
Average target price
909.2
DKK
Spread / Average Target
+0.66%
- Stock Market
- Certificates
- 6B69S Certificat